| 000 | 01794 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515082543.0 | ||
| 264 | 0 | _c20071128 | |
| 008 | 200711s 0 0 eng d | ||
| 022 | _a0953-816X | ||
| 024 | 7 |
_a10.1111/j.1460-9568.2007.05705.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDriver, Joanne E | |
| 245 | 0 | 0 |
_aImpairment of hippocampal gamma-frequency oscillations in vitro in mice overexpressing human amyloid precursor protein (APP). _h[electronic resource] |
| 260 |
_bThe European journal of neuroscience _cSep 2007 |
||
| 300 |
_a1280-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_a3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester _xpharmacology |
| 650 | 0 | 4 |
_aAction Potentials _xdrug effects |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 |
_aAmyloid beta-Protein Precursor _xgenetics |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBiological Clocks _xdrug effects |
| 650 | 0 | 4 |
_aBrain Injuries _xgenetics |
| 650 | 0 | 4 |
_aCalcium Channel Agonists _xpharmacology |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aHippocampus _xphysiopathology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 |
_aKainic Acid _xpharmacology |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Transgenic |
| 650 | 0 | 4 | _aSpectrum Analysis |
| 700 | 1 | _aRacca, Claudia | |
| 700 | 1 | _aCunningham, Mark O | |
| 700 | 1 | _aTowers, Stephen K | |
| 700 | 1 | _aDavies, Ceri H | |
| 700 | 1 | _aWhittington, Miles A | |
| 700 | 1 | _aLeBeau, Fiona E N | |
| 773 | 0 |
_tThe European journal of neuroscience _gvol. 26 _gno. 5 _gp. 1280-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1460-9568.2007.05705.x _zAvailable from publisher's website |
| 999 |
_c17296620 _d17296620 |
||